At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
sunitinib malatedrug
Likely dose
sunitinib malate 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Single Arm, Open Label, Single Institution Study of Neoadjuvant Sunitinib (SUTENT) in Patients With Muscle-Invasive Locally Advanced Transitional Cell Carcinoma of the Bladder
In Brief
A Phase 2 clinical trial evaluating sunitinib malate for Bladder Cancer. Completed, enrolled 9 participants across 1 site.
Detailed Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying the side effects and how well sunitinib works in treating patients with locally advanced bladder cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedSep 2007
Primary CompletionMar 2010
Study CompletionMar 2011
TodayJul 2026
First PostedSep 10, 2007
Enrollment StartSep 1, 2007
Primary CompletionMar 1, 2010
Study CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.8 years ago
Interventions
sunitinib malatedrug
50mg PO daily 4 weeks on -2 weeks off